Cyclo Therapeutics (CYTH.US) Financial Statements - Balance Sheet/Income Statement/Cash Flow

Quote List Quote List

Event Tracking

Jun18

Cyclo Therapeutics Advances NPC1 Phase III Clinical Trial

11:01

Jun11

Cyclo Therapeutics Completes Phase III Clinical Trial Recruitment for NPC Type C1

11:22

Apr24

Cyclo Therapeutics Completes Rare Genetic Disease Clinical Trial Recruitment

20:37

Nov15

Cyclo Therapeutics released FY2024 Q3 earnings on November 14 (EST), actual revenue 233.77 K USD (forecast 294 K USD), actual EPS -0.3074 USD (forecast -0.1566 USD)

04:00

Cyclo Therapeutics released FY2024 Cumulative 3Q Earnings on November 14 (EST), Revenue: 559.33K USD, EPS: -0.6693

04:00

Sep5

Cyclo Therapeutics Releases Preliminary Safety Data for Niemann-Pick Disease Type C1 Treatment

14:29

Schedules & Filings

Schedules

Filings

Nov14

Earning Release(EST)

FY2024 Q3 Earning Release (USD) Revenue 233.77 K, Net Income -8.833 M, EPS -0.3074

Aug14

Earning Release(EST)

FY2024 Q2 Earning Release (USD) Revenue 123.1 K, Net Income -5.981 M, EPS -0.2099

May15

Earning Release(EST)

FY2024 Q1 Earning Release (USD) Revenue 202.45 K, Net Income -4.343 M, EPS -0.1519

Stock List

Top Gainers

Top Decliners

China Concepts

Symbol

Price

%Chg

Change